Bio-Techne Corp

Bio-Techne Corp is a global life sciences company that develops and sells tools and reagents for biomedical research and clinical diagnostics. A core part of its business involves the production of antibodies and other bioactive reagents used in preclinical drug development, which inherently requires animal testing for validation and regulatory compliance. The company is explicitly listed by Cruelty Free Investing for conducting animal testing for its medical products and clinical research.

While the company has partnered with research institutions on initiatives aimed at advancing 3D spatial biology and AI-driven modeling—initiatives cited for their potential to reduce reliance on animal testing—its primary business model remains dependent on traditional animal-based research methods. The recent FDA move to replace animal testing in specific areas, such as monoclonal antibody development, highlights a shifting regulatory landscape, but Bio-Techne's core product lines in research reagents and antibodies continue to serve a market where animal testing is standard practice.